Stay updated with breaking news from Ligand Activated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating) CFO R. Laduane Clifton bought 2,740 shares of the company’s stock in a transaction dated Thursday, May 18th. The shares were acquired at an average cost of $4.95 per share, for a total transaction of $13,563.00. Following the completion of the transaction, the chief financial officer now owns […]
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating) Director John B. Bode purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The stock was acquired at an average cost of $5.04 per share, with a total value of $50,400.00. Following the completion of the acquisition, the director now directly […]
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating) – Cantor Fitzgerald reduced their FY2023 earnings per share estimates for Zevra Therapeutics in a note issued to investors on Tuesday, May 16th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($1.45) for the year, down from their prior estimate […]
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating) CFO R. Laduane Clifton bought 2,740 shares of the company’s stock in a transaction that occurred on Thursday, May 18th. The stock was acquired at an average price of $4.95 per share, for a total transaction of $13,563.00. Following the completion of the acquisition, the chief financial officer […]
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating) traded down 10% during trading on Tuesday . The stock traded as low as $4.41 and last traded at $4.43. 351,489 shares changed hands during mid-day trading, an increase of 51% from the average session volume of 233,420 shares. The stock had previously closed at $4.92. Analyst Upgrades […]